SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Has Consensus Price Target of $10.00 According to Analysts

SOPHiA GENETICS SA (NASDAQ:SOPH) has been assigned a consensus rating of “Hold” from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Several research firms have recently weighed in on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a report on Monday. BTIG Research lifted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st.

Insider Activity

In related news, Chairman Jurgi Camblong sold 40,172 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $326,598.36. Following the sale, the chairman owned 3,395,650 shares of the company’s stock, valued at $27,606,634.50. The trade was a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ross Muken sold 9,838 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $79,982.94. Following the completion of the sale, the chief executive officer directly owned 660,391 shares in the company, valued at approximately $5,368,978.83. This represents a 1.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 282,543 shares of company stock valued at $2,130,026. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SOPH. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $50,000. Royal Bank of Canada raised its position in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the last quarter. AXQ Capital LP acquired a new position in shares of SOPHiA GENETICS in the second quarter worth approximately $119,000. Silverberg Bernstein Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after acquiring an additional 4,155 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS in the second quarter worth approximately $567,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Trading Down 2.6%

NASDAQ SOPH opened at $7.22 on Tuesday. The company has a market cap of $605.69 million, a price-to-earnings ratio of -6.28 and a beta of 0.95. SOPHiA GENETICS has a twelve month low of $3.75 and a twelve month high of $8.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The business’s fifty day moving average is $7.94 and its 200 day moving average is $6.18.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, sell-side analysts expect that SOPHiA GENETICS will post -0.77 EPS for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.